vs
NORTHRIM BANCORP INC（NRIM）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
NORTHRIM BANCORP INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.7倍（$61.2M vs $35.5M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 11.6%），NORTHRIM BANCORP INC自由现金流更多（$133.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 18.4%）
Northrim Bancorp Inc是总部位于美国阿拉斯加州的区域银行控股企业，提供商业及个人存贷款、按揭产品、财富管理等多元化金融服务，服务覆盖本地小微企业、个人消费者及企业客户群体。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
NRIM vs RXRX — 直观对比
营收规模更大
NRIM
是对方的1.7倍
$35.5M
营收增速更快
RXRX
高出670.2%
11.6%
自由现金流更多
NRIM
多$181.2M
$-47.3M
两年增速更快
RXRX
近两年复合增速
18.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $61.2M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | 79.9% | 59.8% |
| 营业利润率 | 27.2% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | 11.6% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $-2.80 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRIMRXRX
| Q4 25 | $61.2M | $35.5M | ||
| Q3 25 | $77.2M | $5.2M | ||
| Q2 25 | $61.4M | $19.2M | ||
| Q1 25 | $55.8M | $14.7M | ||
| Q4 24 | $54.8M | $4.5M | ||
| Q3 24 | $51.0M | $26.1M | ||
| Q2 24 | $46.5M | $14.4M | ||
| Q1 24 | $43.7M | $13.8M |
净利润NRIMRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $27.1M | $-162.3M | ||
| Q2 25 | $11.8M | $-171.9M | ||
| Q1 25 | $13.3M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $8.8M | $-95.8M | ||
| Q2 24 | $9.0M | $-97.5M | ||
| Q1 24 | $8.2M | $-91.4M |
毛利率NRIMRXRX
| Q4 25 | 79.9% | 59.8% | ||
| Q3 25 | 84.0% | -183.8% | ||
| Q2 25 | 78.5% | -4.9% | ||
| Q1 25 | 84.1% | -48.0% | ||
| Q4 24 | 77.8% | -181.4% | ||
| Q3 24 | 75.2% | 53.7% | ||
| Q2 24 | 79.1% | 36.2% | ||
| Q1 24 | 78.2% | 19.1% |
营业利润率NRIMRXRX
| Q4 25 | 27.2% | -304.8% | ||
| Q3 25 | 44.8% | -3327.6% | ||
| Q2 25 | 25.7% | -916.8% | ||
| Q1 25 | 31.5% | -1297.9% | ||
| Q4 24 | 24.3% | -4042.4% | ||
| Q3 24 | 22.8% | -377.1% | ||
| Q2 24 | 24.9% | -697.4% | ||
| Q1 24 | 24.1% | -698.4% |
净利率NRIMRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 35.1% | -3135.3% | ||
| Q2 25 | 19.2% | -894.2% | ||
| Q1 25 | 23.9% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 17.3% | -367.5% | ||
| Q2 24 | 19.4% | -676.6% | ||
| Q1 24 | 18.8% | -662.4% |
每股收益（稀释后）NRIMRXRX
| Q4 25 | $-2.80 | $-0.17 | ||
| Q3 25 | $1.20 | $-0.36 | ||
| Q2 25 | $2.09 | $-0.41 | ||
| Q1 25 | $2.38 | $-0.50 | ||
| Q4 24 | $-1.83 | $-0.56 | ||
| Q3 24 | $0.39 | $-0.34 | ||
| Q2 24 | $1.62 | $-0.40 | ||
| Q1 24 | $1.48 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $12.8M | $9.6M |
| 股东权益账面价值 | $326.5M | $1.1B |
| 总资产 | $3.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.04× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资NRIMRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务NRIMRXRX
| Q4 25 | $12.8M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $23.0M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益NRIMRXRX
| Q4 25 | $326.5M | $1.1B | ||
| Q3 25 | $315.7M | $1.0B | ||
| Q2 25 | $290.2M | $919.1M | ||
| Q1 25 | $279.8M | $933.9M | ||
| Q4 24 | $267.1M | $1.0B | ||
| Q3 24 | $260.1M | $524.6M | ||
| Q2 24 | $247.2M | $584.4M | ||
| Q1 24 | $239.3M | $401.2M |
总资产NRIMRXRX
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | $3.3B | $1.4B | ||
| Q2 25 | $3.2B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.0B | $1.4B | ||
| Q3 24 | $3.0B | $726.5M | ||
| Q2 24 | $2.8B | $775.9M | ||
| Q1 24 | $2.8B | $557.8M |
负债/权益比NRIMRXRX
| Q4 25 | 0.04× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.09× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $139.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $133.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 218.9% | -133.1% |
| 资本支出强度资本支出/营收 | 8.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $235.4M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流NRIMRXRX
| Q4 25 | $139.3M | $-46.1M | ||
| Q3 25 | $92.7M | $-117.4M | ||
| Q2 25 | $-4.4M | $-76.4M | ||
| Q1 25 | $16.5M | $-132.0M | ||
| Q4 24 | $-8.7M | $-115.4M | ||
| Q3 24 | $-201.0K | $-59.2M | ||
| Q2 24 | $-38.5M | $-82.2M | ||
| Q1 24 | $-5.5M | $-102.3M |
自由现金流NRIMRXRX
| Q4 25 | $133.9M | $-47.3M | ||
| Q3 25 | $89.9M | $-117.6M | ||
| Q2 25 | $-4.7M | $-79.6M | ||
| Q1 25 | $16.3M | $-133.8M | ||
| Q4 24 | $-9.3M | $-116.7M | ||
| Q3 24 | $-330.0K | $-63.8M | ||
| Q2 24 | $-39.4M | $-83.4M | ||
| Q1 24 | $-6.6M | $-109.0M |
自由现金流率NRIMRXRX
| Q4 25 | 218.9% | -133.1% | ||
| Q3 25 | 116.5% | -2272.5% | ||
| Q2 25 | -7.7% | -413.9% | ||
| Q1 25 | 29.3% | -907.4% | ||
| Q4 24 | -17.1% | -2567.7% | ||
| Q3 24 | -0.6% | -244.6% | ||
| Q2 24 | -84.7% | -578.5% | ||
| Q1 24 | -15.1% | -789.9% |
资本支出强度NRIMRXRX
| Q4 25 | 8.9% | 3.5% | ||
| Q3 25 | 3.5% | 4.7% | ||
| Q2 25 | 0.5% | 16.4% | ||
| Q1 25 | 0.4% | 12.4% | ||
| Q4 24 | 1.1% | 28.6% | ||
| Q3 24 | 0.3% | 17.5% | ||
| Q2 24 | 1.9% | 8.2% | ||
| Q1 24 | 2.4% | 48.2% |
现金转化率NRIMRXRX
| Q4 25 | — | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | -4.27× | — | ||
| Q1 24 | -0.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIM
| Community Banking Segment | $44.3M | 72% |
| Specialty Finance Segment | $7.4M | 12% |
| Other | $4.7M | 8% |
| Home Mortgage Lending Segment | $3.6M | 6% |
| Credit And Debit Card | $1.2M | 2% |
RXRX
暂无分部数据
